NovAliX is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry's outsourcing needs from discovery to manufacturing.
With proprietary SPR technology, X-ray protein crystallography, supramolecular mass spectrometry and chemistry, NovAliX offers comprehensive integrated services for small molecule drug discovery.
With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams.
NovAliX Group, a team of 120 scientists, is located in state-of-the-art laboratory facilities in Strasbourg-Illkirch (France) and Heidelberg (Germany), and has a global footprint with clients around the world.
For drug discovery, NovAliX offers target-driven solutions from hit finding to lead optimization by combining its chemistry and structural biology original expertise with outstanding biophysical technologies.
NovAliX further supports small molecules programs with process R&D experience, know-how and capabilities.